1 citations,
January 2021 in “Wits Journal of Clinical Medicine” Long COVID causes lasting symptoms and needs ongoing care.
December 2024 in “Revista Eletrônica Perspectivas da Ciência e Tecnologia - ISSN 1984-5693” Polymeric nanoparticles could improve hair loss treatments by delivering drugs more effectively to hair follicles.
September 2024 in “Journal of the American Academy of Dermatology” Low-dose oral minoxidil helps hair regrowth in COVID-19-related hair loss with few side effects.
February 2024 in “PubMed” More people experience hair loss after recovering from COVID-19 in hospitals than in outpatient settings.
December 2023 in “Damianus Journal of Medicine” Post-COVID-19 patients are at risk for hair loss.
September 2023 in “Brazilian Journal of Health Review” COVID-19 may cause a common type of hair loss called telogen effluvium.
July 2023 in “Zenodo (CERN European Organization for Nuclear Research)” COVID-19 can cause temporary hair loss in some patients, affecting their quality of life.
June 2023 in “BMC Pharmacology and Toxicology” The trial will test if proxalutamide is safe and effective in reducing death in severe COVID-19 patients.
May 2023 in “Journal of contemporary medicine” Using Favipiravir, a COVID-19 treatment drug, likely doesn't cause hair loss.
April 2023 in “Journal of Investigative Dermatology” Protein analysis shows aging changes in scalp cell types from women.
April 2023 in “The journal of investigative dermatology/Journal of investigative dermatology” Psoriasis patients on biologic therapy have a weaker immune response to COVID-19 vaccination than healthy people.
Post-COVID-19 patients often experience musculoskeletal issues, fitness decline, behavioral changes, chest pain, cough, hair loss, and nervous system problems.
January 2023 in “Al-Azhar International Medical Journal /Al-Azhar International Medical Journal” Hair loss is not clearly linked to COVID-19 vaccination in Egyptians.
December 2022 in “Journal of Education, Health and Sport” COVID-19 can cause hair loss, often treated effectively with a combination of supplements and topical treatments.
November 2022 in “Revista Hospital Clínico Universidad de Chile” COVID-19 may cause hair loss due to the virus's effects and stress from the pandemic.
November 2022 in “Journal of Investigative Dermatology” Skin aging and cancer development are influenced by the competition between stem cells.
November 2022 in “Journal of Investigative Dermatology” Low oxygen levels affect the behavior of certain proteins in human skin cells.
November 2022 in “Journal of Investigative Dermatology” Human-induced stem cell-created skin models can help understand skin diseases by studying the skin's layers.
September 2022 in “Research, Society and Development” Long-lasting symptoms like fatigue and breathlessness can persist after COVID-19, requiring ongoing medical follow-up.
September 2021 in “Medicina estética” Sabal serrulata and biomimetic peptides with microneedling reduced hair loss and improved hair thickness in men with balding.
December 2020 in “Dermatology archives” Some COVID-19 pneumonia patients in Veracruz, Mexico, had skin issues, with reversible hair loss linked to disease severity.
June 2020 in “Dermatologic therapy” Using Janus kinase inhibitors (JAKi) in COVID-19 treatment requires careful consideration due to their immunosuppressive effects.
December 2023 in “International Journal of Research in Dermatology” Hormonal imbalances are important in the development of male pattern baldness.
October 2022 in “Cosmoderma” October 2021 in “Journal of Investigative Dermatology” No significant link between male pattern baldness and severe Covid-19, but some shared biological pathways exist.
June 2020 in “Faculty Opinions – Post-Publication Peer Review of the Biomedical Literature” 353 citations,
February 2022 in “Nature Immunology” Long-haul COVID can cause lasting symptoms affecting many body systems and may be linked to ongoing inflammation and immune system issues.
151 citations,
May 2021 in “Frontiers in Medicine” Many patients experience long-lasting symptoms like fatigue and pain after COVID-19, regardless of initial disease severity.
42 citations,
July 2021 in “Frontiers in Medicine” Proxalutamide significantly lowered hospital admissions for male COVID-19 patients compared to a placebo.